Please assess the completion status of the following clinical trial:

Trial Title: Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years of age inclusive~* Type 1 or type 2 diabetes mellitus~* History of symptoms of gastroparesis for at least 3 months leading up to the Screening Visit~* Documented delayed gastric emptying~* Upper gastrointestinal obstruction ruled out by endoscopy or barium scan~* Concomitant medications must be stable for at least 2 weeks leading up to the Screening visit and must be maintained during the study.~* Females of child-bearing potential must have a negative serum pregnancy test and use (and agree to continue to use throughout the study) an acceptable form of contraception~Exclusion Criteria:~* Gastrectomy, bariatric surgery, fundoplication or vagotomy/pyloroplasty~* Has had or plans to have endoscopic pyloric injections of botulinum toxin within 6 months prior to the Screening Visit or during the study~* NG, PEG or PEJ feeding tube or inpatient hospitalization for gastroparesis within 2 weeks prior to the Screening Visit~* Required parenteral nutrition for treatment of gastroparesis within 2 months prior to the Screening Visit~* Active gastric pacemaker within 3 months prior to the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TZP-102 three times a day (Type: EXPERIMENTAL): 10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
- Placebo three times a day (Type: PLACEBO_COMPARATOR): Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).